High-performance liquid chromatography of HIV protease inhibitors in human biological matrices

被引:28
作者
Aarnoutse, RE
Wissen, CPWGMVV
Underberg, WJM
Kleinnijenhuis, J
Hekster, YA
Burger, DM
机构
[1] Univ Nijmegen, Med Ctr, Dept Clin Pharm, NL-6500 HB Nijmegen, Netherlands
[2] Univ Utrecht, Fac Pharm, Dept Pharmaceut Anal, NL-3584 CA Utrecht, Netherlands
来源
JOURNAL OF CHROMATOGRAPHY B | 2001年 / 764卷 / 1-2期
关键词
reviews; protease inhibitors;
D O I
10.1016/S0378-4347(01)00344-9
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Methods for HPLC analysis of protease inhibitors (Pls) in human biological matrices were reviewed. Assays have been developed for analysis of single PIs or for simultaneous measurement of multiple PIs in plasma-serum, saliva, cerebrospinal fluid and semen. Liquid-liquid extraction was most often applied for sample pretreatment but solid-phase extraction and protein precipitation were used as well. Reversed-phase or ion-pair chromatography have been used to separate PIs. Detection of Pls should be sensitive enough for quantitation of plasma concentrations below trough levels of single Pls, or below proposed therapeutic thresholds for Pls. The large majority of assays employs UV detection. As the potential for interferences is large, the selectivity of every method should be evaluated properly. The available high-performance liquid chromatography (HPLC) methods have been applied in clinical pharmacokinetic studies and for therapeutic drag monitoring of Pls. Participation in an interlaboratory quality control program is recommended for every laboratory engaged in the bioanalysis of PIs. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:363 / 384
页数:22
相关论文
共 84 条
  • [11] Sensitive and rapid method for the simultaneous quantification of the HIV-protease inhibitors indinavir, nelfinavir, ritonavir, and saquinavir in human plasma by reversed-phase liquid chromatography
    Bouley, M
    Briere, C
    Padoin, C
    Petitjean, O
    Tod, M
    [J]. THERAPEUTIC DRUG MONITORING, 2001, 23 (01) : 56 - 60
  • [12] BRUNDAGE RC, 2000, 1 INT WORKSH CLIN PH
  • [13] Once-daily indinavir plus ritonavir: preliminary results of the PIPO study
    Burger, DM
    Hugen, PWH
    van der Ende, ME
    van Wijngaarden, P
    Aarnoutse, RE
    Reiss, P
    Lange, JMA
    [J]. AIDS, 2000, 14 (16) : 2621 - 2623
  • [14] Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography
    Burger, DM
    de Graaff, M
    Wuis, EW
    Koopmans, PP
    Hekster, YA
    [J]. JOURNAL OF CHROMATOGRAPHY B, 1997, 703 (1-2): : 235 - 241
  • [15] Burger DM, 1998, ANTIVIR THER, V3, P215
  • [16] BURGER DM, 2000, AIDS S, V14, P258
  • [17] BURGER DM, 2001, 2 INT WORKSH CLIN PH
  • [18] CHAMBERLAIN J, 1995, ANAL DRUGS BIOL FLUI, P65
  • [19] HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC DETERMINATION OF A POTENT AND SELECTIVE HIV PROTEASE INHIBITOR (L-735,524) IN RAT, DOG AND MONKEY PLASMA
    CHEN, IW
    VASTAG, KJ
    LIN, JH
    [J]. JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 672 (01): : 111 - 117
  • [20] CLEVENBERGH P, 2001, 2 INT WORKSH CLIN PH